Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunoglobulin amyloidosis]

O Hermine1, P Bourquelot, A Buzyn

  • 1Service d'hématologie, INSERM U25, Groupe hospitalier Necker-Enfants malades, Paris.

La Revue Du Praticien
|February 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and outcomes of patients with pediatric-onset non-mastocytosis mast cell activation disorders: A CEREMAST study.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology·2026
Same author

Ibrutinib-induced spontaneous penile hematoma.

Annales de dermatologie et de venereologie·2025
Same author

KIT-Targeting Drugs in the Management of Nonadvanced and Advanced Systemic Mastocytosis.

The journal of allergy and clinical immunology. In practice·2025
Same author

Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A high prevalence of hereditary alpha-tryptasemia in pediatric mastocytoma.

Allergy·2024
Same author

Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects.

Blood·2021

AL amyloidosis is a rare disease diagnosed by histopathology, secondary to immunoglobulin light chain synthesis. Research is advancing understanding of amyloid fibril formation and exploring new treatments targeting the immunoglobulin-producing clone.

Area of Science:

  • Hematology
  • Pathology
  • Biochemistry

Context:

  • AL amyloidosis is a rare plasma cell disorder.
  • Diagnosis relies on histopathology and identification of monoclonal immunoglobulin light chains.
  • Pathophysiology involves structural anomalies leading to amyloid fibril formation.

Purpose:

  • To summarize current understanding of AL amyloidosis pathophysiology.
  • To highlight diagnostic criteria and challenges.
  • To review prognostic factors and emerging therapeutic strategies.

Summary:

  • AL amyloidosis results from monoclonal immunoglobulin light chain synthesis, often associated with plasma cell disorders like myeloma.
  • The clinical presentation is heterogeneous, influenced by organ involvement (cardiac, renal, neurologic, gastrointestinal).

Related Experiment Videos

  • Prognosis is poor, depending on disease extent and underlying hematologic conditions. Treatment focuses on reducing the source of immunoglobulin production.

    • Impact:

    • Improved understanding of AL amyloidosis pathogenesis.
    • Identification of key factors influencing patient prognosis.
    • Potential for novel therapeutic approaches targeting amyloid fibril formation and clone elimination.